HC Wainwright Issues Pessimistic Forecast for Dyne Therapeutics (NASDAQ:DYN) Stock Price

Dyne Therapeutics (NASDAQ:DYN) had its price objective cut by HC Wainwright from $55.00 to $46.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the stock.

A number of other analysts have also issued reports on DYN. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Royal Bank of Canada reiterated an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Finally, Robert W. Baird initiated coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $48.64.

Dyne Therapeutics Stock Up 3.3 %

Shares of NASDAQ:DYN opened at $13.61 on Friday. The company has a 50-day moving average price of $16.98 and a two-hundred day moving average price of $27.73. Dyne Therapeutics has a twelve month low of $12.87 and a twelve month high of $47.45. The firm has a market capitalization of $1.39 billion, a PE ratio of -3.82 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.04. Analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,334 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the completion of the sale, the insider now owns 201,685 shares in the company, valued at $5,671,382.20. The trade was a 1.14 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Richard William Scalzo sold 1,455 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $40,914.60. Following the completion of the sale, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. This represents a 1.13 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,387 shares of company stock valued at $142,789 over the last 90 days. 20.77% of the stock is owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds have recently made changes to their positions in DYN. State of New Jersey Common Pension Fund D purchased a new position in Dyne Therapeutics in the 3rd quarter worth $1,588,000. Jennison Associates LLC increased its holdings in shares of Dyne Therapeutics by 1.5% in the third quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock worth $48,383,000 after buying an additional 19,730 shares during the period. abrdn plc bought a new stake in shares of Dyne Therapeutics in the 4th quarter valued at about $608,000. RA Capital Management L.P. boosted its holdings in Dyne Therapeutics by 5.5% during the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after acquiring an additional 331,940 shares during the period. Finally, Geode Capital Management LLC grew its position in Dyne Therapeutics by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock worth $66,802,000 after acquiring an additional 84,760 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.